新修订药品管理法实施条例公布 儿童药罕见病药迎创新激励

Core Viewpoint - The newly revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" aims to enhance drug regulation and innovation, with a focus on pediatric and rare disease medications, and will take effect on May 15, 2026 [1] Group 1: Regulatory Changes - The revised regulations represent the first comprehensive update since 2002, reflecting significant changes in drug research, production, distribution, and usage over the past 23 years [1] - The regulations introduce a market exclusivity period for pediatric and rare disease medications, providing up to 7 years of exclusivity for qualifying drugs, contingent on the commitment to ensure supply [2][3] - The regulations establish a data protection system for trial data related to new chemical entities, preventing unauthorized commercial use of undisclosed data [2] Group 2: Support for Innovation - The regulations emphasize support for drug development and innovation driven by clinical value, encouraging the research and creation of new drugs [1] - A breakthrough therapy designation and expedited registration processes are introduced to accelerate the approval of innovative drugs [3] Group 3: Quality and Safety Management - Drug marketing authorization holders are required to establish comprehensive quality assurance and pharmacovigilance systems, ensuring ongoing evaluation of drug quality throughout its lifecycle [3] - The regulations clarify the responsibilities of online drug sales platforms, mandating them to implement strict oversight and management of drug transactions [3] Group 4: Traditional Chinese Medicine (TCM) and Institutional Management - The regulations promote quality management standards for TCM production, encouraging local governments to develop relevant plans [4] - The management of medical institution preparations is strengthened, allowing for the formulation of pediatric medications and detailing the approval and usage processes [4]